PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 19, 2026Clinical Cancer Research

Abstract PS1-09-29: A Rapid Digital Patient-Derived Organoid Guiding Therapy After Antibody Drug Conjugates (ADC)s In Patients with Metastatic Breast CancerYY1 YY1The size limit (including title and body) is 3,400 characters; this does not include spaces

View Full Paper
Ask AI
Bookmark
Share

Authors

YYY. YuanJBJin Sun BitarDLD. Lin

Discussion

Loading...

Member takes

Overview

Prospective clinical study assesses drug response in metastatic breast cancer using digital organoids, suggesting personalized treatment strategies.

Key Points

  • This study aims to evaluate the effectiveness of a digital patient-derived organoid platform to predict treatment responses in patients with metastatic breast cancer after antibody drug conjugate therapy.
  • Established an IRB for collecting fresh tumor biopsies from metastatic breast cancer patients treated with ADCs.
  • Generated digital patient-derived organoids from fresh tumor samples for assessing drug sensitivity.
  • Conducted dosing experiments with various ADCs and chemotherapy agents to evaluate organoid responses.
  • 28 tumor tissues were processed, yielding a 57.9% success rate in establishing viable organoids.
  • Prior exposure to ADCs correlated with reduced sensitivity of organoids to the same agents, indicating acquired resistance.
  • DPOs from heavily pretreated patients remained responsive to alternative therapies, suggesting new treatment opportunities.

Cite This Study

Yuan et al. (2026) studied this question.

synapsesocial.com/papers/6996a84cecb39a600b3eeeb9https://doi.org/10.1158/1557-3265.sabcs25-ps1-09-29
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Rapid digital patient-derived organoid testing for guiding therapy in patients with metastatic breast cancer receiving antibody drug conjugates (ADCs).2026
  2. 2Abstract PD3-09: Molecular characterization of resistance to antibody drug conjugates in metastatic breast cancer: a prospective analysis from the AURORA US Network2026
  3. 3Abstract 4397: Leveraging patient-derived organoids to investigate bystander effects of antibody-drug conjugates in solid tumor backgrounds2026
  4. 4Abstract 241: Patient-derived organoids as a reliable screening platform for assessing ADC efficacy and specificity2024 · 1 citations
  5. 5Abstract 1388: Ex vivo micro-tumor testing platform to guide patient stratification for clinical development of ADCs.2026